9397eae883358a8d0271d78a3f1cab48455a90d9e485197636d0691bb8d87f2e

Net Sales (USD, millions)

Other Revenues (USD, millions)

Total Revenues (USD, millions)

Cost of Sales (USD, millions)

Gross Profit (USD, millions)

Research and Development Expenses (USD, millions)

Acquired IPR&D (USD, millions)

Selling, General and Administrative Expenses (USD, millions)

Litigation settlements and other contingencies, net (USD, millions)

Total Operating Expenses (USD, millions)

Earnings (Loss) from Operations (USD, millions)

Interest Expense (USD, millions)

Other Income (Expense), Net (USD, millions)

Earnings (Loss) Before Income Taxes (USD, millions)

Income Tax (Benefit) Provision (USD, millions)

Net Earnings (Loss) (USD, millions)

Basic Earnings (Loss) per Share (USD)

Diluted Earnings (Loss) per Share (USD)

Weighted Average Shares Outstanding - Basic (Millions)

Weighted Average Shares Outstanding - Diluted (Millions)

7f9a8108c44eb7807690c9f8abd9090574f081b03339e423e02f120caa8b7d69

Cash and Cash Equivalents (USD, millions)

Accounts Receivable, Net (USD, millions)

Inventories (USD, millions)

Prepaid Expenses and Other Current Assets (USD, millions)

Total Current Assets (USD, millions)

Intangible Assets, Net (USD, millions)

Goodwill (USD, millions)

Other Assets (USD, millions)

Total Assets (USD, millions)

Current Portion of Long-Term Debt and Other Long-Term Obligations (USD, millions)

Other Current Liabilities (USD, millions)

Long-Term Debt (USD, millions)

Other Long-Term Obligations (USD, millions)

Total Liabilities (USD, millions)

Total Equity (USD, millions)

Total Liabilities and Equity (USD, millions)

51e708c953bb3c182d167df135cf867b7d474dfb35e74303d874c5959d835d2c

Adjustments for Non-Cash Items

Stock-Based Compensation

Changes in Working Capital

Capital Expenditures (CapEx)

Proceeds from / Repayments of Debt

Share Repurchases

Dividend Payments

Net Change in Cash

68b04869c1de80e3f1fe671e4ec4d5f0d28d5cfd4782b88e485a17c84a580bd7

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

1a655ddfcfd168f696a8603c524123a0969215837076df0e1f275b471c5bc915

Current Assets [USD, Millions]

Cash and Cash Equivalents [USD, Millions]

Accounts Receivable [USD, Millions]

Inventory [USD, Millions]

Non-Current Assets [USD, Millions]

Property, Plant, and Equipment (PP&E) [USD, Millions]

Goodwill [USD, Millions]

Intangible Assets [USD, Millions]

Current Liabilities [USD, Millions]

Accounts Payable [USD, Millions]

Short-term Debt [USD, Millions]

Accrued Expenses [USD, Millions]

Non-Current Liabilities [USD, Millions]

Long-term Debt [USD, Millions]

Lease Liabilities [USD, Millions]

Deferred Tax Liabilities [USD, Millions]

Shareholders' Equity [USD, Millions]

Retained Earnings [USD, Millions]

Common Stock [USD, Millions]

Additional Paid-in Capital [USD, Millions]

9462d87d73fa58e00afdc33fe56127db938a2f6548a396038201ea0de5e0c831

Number of patients served annually (billion patients)

Number of employees (employees)

Number of manufacturing and packaging sites (sites)

Number of countries and territories served (countries and territories)

d12ae6d4f005ada732b6bc02510174a8d1b08fcfe4fead4d4465b0b13af3186e

Brands

Generics

- Developed Markets

- Greater China

- JANZ

- Emerging Markets

Complex Generics (Complex Gx)

Developed Markets

Greater China

JANZ

Emerging Markets

Total Revenue

f50f6520d5817572627f0145e4a5faf18b261379e837d74097031aa05282197d

- United States

- China

Total Net Sales

32de83a9a263edd85c9ebe73382dadb0e18c1455dcd7979130b0cd5e6637927c

Viatris (VTRS)

Financials